ArticleBMC clinical pathology2014
Serum TFF3 may be a pharamcodynamic marker of responses to chemotherapy in gastrointestinal cancers.
Article in BMC clinical pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Gastric cancer detection by non-blood-based liquid biopsies: A systematic review looking into the last decade of research.United European gastroenterology journal · 2023Pooled it
- Pronounced ethnic and sex disparities in gastric cancer burden and healthcare utilization in Inner Mongolia: a 9-year population-based cohort study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2026Article
- Diagnostic utility of trefoil factor families for the early detection of lung cancer and their correlation with tissue expression.Oncology letters · 2023Article
- Gene expression analysis of human prostate cell lines with and without tumor metastasis suppressor CD82.BMC cancer · 2020Article
- Article
- Trefoil Factor 3 (TFF3) Is Involved in Cell Migration for Skeletal Repair.International journal of molecular sciences · 2019Article
- Prognostic Value of Trefoil Factor 3 Expression in Patients with Gastric Cancer.World journal of surgery · 2018Article
- Downregulation of trefoil factor-3 expression in the rectum is associated with the development of ulcerative colitis-associated cancer.Oncology letters · 2018Article
- TFF3 Contributes to Epithelial-Mesenchymal Transition (EMT) in Papillary Thyroid Carcinoma Cells via the MAPK/ERK Signaling Pathway.Journal of Cancer · 2018Article
- Localization of trefoil factor family peptide 3 (TFF3) in epithelial tissues originating from the three germ layers of developing mouse embryo.Bosnian journal of basic medical sciences · 2017Article
- Plasma expression of the intestinal metaplasia markers CDH17 and TFF3 in patients with gastric cancer.Cancer biomarkers : section A of Disease markers · 2017Article
- Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.Clinical pharmacology and therapeutics · 2017Article
- Diagnostic value evaluation of trefoil factors family 3 for the early detection of colorectal cancer.World journal of gastroenterology · 2017Article
- Reproductive factors, hormone use and gastric cancer risk: The Singapore Chinese Health Study.International journal of cancer · 2016Article
- Trefoil factor 3 as a novel biomarker to distinguish between adenocarcinoma and squamous cell carcinoma.Medicine · 2015Article
- Trefoil Factor 3 (TFF3) Is Regulated by Food Intake, Improves Glucose Tolerance and Induces Mucinous Metaplasia.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs a secreted protein, serum trefoil factor 3 (TFF3) has been reported to be a biomarker of several malignancies. We further investigated whether TFF3 can be applied as a biomarker for and predictor of responses to chemotherapy in gastrointestinal cancer.
methodsSerum and urine samples were collected from 90 patients with gastric cancer, 128 patients with colorectal cancer and 91 healthy individuals. Serum and urine TFF3 levels were measured using an ELISA.
resultsSerum and urine TFF3 levels were significantly higher in the patients with gastric and colorectal cancer compared with the healthy individuals (P < 0.05). Higher serum levels of TFF3 were significantly correlated with distant metastasis and an advanced stage in the two types of cancer (P < 0.05). Age and the number of lymph node metastases were significantly correlated with serum TFF3 levels in colorectal cancer, and decreased serum TFF3 levels were significantly correlated with responses to chemotherapy in both the gastric and the colorectal cancer partial response (PR) groups. A combination of serum and urine data did not significantly improve the detection of either cancer, although urine levels have shown a significant negative relationship with the glomerular filtration rate (GFR).
conclusionsOur data indicate that TFF3 may be an effective biomarker of tumor stage and the presence of distant metastasis, and may be a pharmacodynamic marker of response to chemotherapy in gastrointestinal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.